Efficacy and safety of omalizumab therapy in urticaria vasculitis
Urticarial vasculitis (UV) is a small-vessel leukocytoclastic vasculitis characterized by different clinical manifestations ranging from long-lasting urticarial lesions to severe and potentially life-threatening multi-organ involvement. Omalizumab (OMA), anti-IgE recombinant humanized IgG1 monoclona...
Main Authors: | Fiorella Petrelli, Daiana Giannini, Silvia Bilia, Isabella Del Corso, Valeria Rocchi, Paola Migliorini, Ilaria Puxeddu |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-07-01
|
Series: | Frontiers in Allergy |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/falgy.2022.952079/full |
Similar Items
-
Normocomplementaemic urticarial vasculitis: effective treatment with omalizumab
by: Marianne de Brito, et al.
Published: (2018-09-01) -
Down-titration of omalizumab in a patient with chronic spontaneous urticaria
by: Pinuccia Omodeo
Published: (2018-12-01) -
Omalizumab for Chronic Urticaria: A Case Series and Overview of the Literature
by: Ilya Ivyanskiy, et al.
Published: (2012-01-01) -
Treatment of chronic urticaria with omalizumab: the experience of Hospital de Braga
by: Ana G. Lopes, et al.
Published: (2022-10-01) -
Omalizumab for chronic urticaria in Latin America
by: Paul Wilches, et al.
Published: (2016-11-01)